PRODRUGS FOR NITROREDUCTASE BASED CANCER THERAPY- 2: Novel amide/Ntr combinations targeting PC3 cancer cells
作者:Tuğba Güngör、Ferah Cömert Önder、Esra Tokay、Ünzile Güven Gülhan、Nelin Hacıoğlu、Tuğba Taşkın Tok、Ayhan Çelik、Feray Köçkar、Mehmet Ay
DOI:10.1016/j.ejmech.2019.03.035
日期:2019.6
techniques in this study. Prodrug candidates were studied on reduction potentials with Ssap-NtrB by HPLC system. Also, cyototoxic properties and prodrug ability of these amides were investigated using different cancer cell lines such as Hep3B and PC3. As a result of theoretical and biological studies, combinations of A5, A6 and A20 with Ssap-NtrB can be suggested as potential prodrugs/enzyme combinations
在GDEPT(基因定向酶前药治疗)研究中使用NAD(P)H催化硝基还原酶(NTR)催化硝基化合物还原的研究非常显着,该研究可最大程度降低健康细胞的毒性并增加癌细胞中药物的浓度。发现新的前药/ NTR组合是替代已知的前药候选物(例如CB1954,SN23862,PR-104A)所必需的。为了这个目的,设计,合成并在计算机上进行了含硝基的芳香族酰胺(A1-A23)2的合成。本研究中的ADMET和分子对接技术。通过HPLC系统,用Ssap-NtrB研究了前药候选物的还原电位。此外,使用不同的癌细胞系(例如Hep3B和PC3)研究了这些酰胺的细胞毒性和前药能力。作为理论和生物学研究的结果,与CB1954 / NfsB相比,A5,A6和A20与Ssap-NtrB的组合可能被建议作为基于NTR的癌症治疗的潜在前药/酶组合。